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Abstract 
The indiscriminate, cytotoxic nature of anti-cancer treatments causes gastrointestinal mucositis 
(GIM), an inflammatory gut state that underpins a constellation of significant clinical and 
economic consequences, including diarrhoea and increased costs of care. The current lack of 
effective treatment options has been attributed to a poor understanding of targetable GIM 
mechanisms. Therefore, this study aimed to quantify how suspected pathobiological contributor, 
serotonin (5-HT), production and receptor expression changed following chemotherapy, using a 
well-established, preclinical model of GIM. Tumour bearing Dark Agouti rats received either two 
doses of methotrexate or saline, and were assessed for validated markers of GIM, diarrhoea and 
weight loss. Rats were killed 72 hours after initial methotrexate treatment. 5-HT production was 
assessed in the jejunum and colon by immunofluorescence, in which 5-HT+ cells were counted 
and normalised to tissue area, and by qPCR, to quantify 5-HT production enzyme, Tph1, 
expression. Further qPCR was conducted for receptors, 5-HT2A and 5-HT2B. Methotrexate-treated 
rats displayed lower levels of jejunal 5-HT+ cells/m2 (control: 0.0051±0.0010, MTX: 
0.00045±0.00020, **P=0.0013), as well as relative Tph1 (control: 470±270, MTX: 41±16, 
**P=0.0087) and 5-HT2B (control: 9500±3300, MTX: 730±390, **P=0.0079) mRNA expression. 
These findings suggest a potential anti-inflammatory role of 5-HT in GIM, which may be mediated 
through the 5-HT2B receptor, and support further investigation of the translational potential of 
maintaining 5-HT production to minimise local GIM and related systemic toxicities.  
 3 
Introduction 
Although recent and significant advances in medicine have improved cancer survival rates and 
time living after diagnosis,1 they have also exacerbated the ever-prominent, yet widely under-
recognised physical and psychological consequences of cancer treatment.2 One such consequence 
is gastrointestinal mucositis (GIM), an acute side effect of cytotoxic cancer therapy characterised 
by inflammation of the gastrointestinal mucosa,3 which occurs when highly regenerative cell 
populations become unintended targets of non-selective chemo- and radiotherapy.4 For the 70% 
of chemotherapy recipients that experience mucositis,4 they must not only navigate the burden of 
cancer, but must also endure troublesome and debilitating clinical manifestations, such as 
diarrhoea, abdominal bloating and significant pain.3 Furthermore, these symptoms create a multi-
faceted burden, encompassing clinical, psychosocial and economic factors, which impacts the 
affected individual, their family and friends, and the healthcare system.5, 6 
An extensive GIM knowledge base has been established, particularly in terms of initiating factors 
and key tissue changes. Fundamental GIM pathogenesis has been classified into five distinct yet 
overlapping stages, and key hallmark characteristics have been identified as villous atrophy, 
shallow crypts, ulceration and inflammation.7, 8 This knowledge assisted in the development of 
new clinical practice guidelines, with several strategies for oral mucositis now exisiting.9 
Unfortunately, this level of progress is unmatched for GIM, with current interventions only 
mediating symptoms, rather than addressing key underlying mechanisms.9 
Controlling GIM is particularly challenging as it is initiated by the same cytotoxic mechanisms 
that contribute to the efficacy of anticancer therapies.10 To avoid impairing treatment efficacy, 
novel interventions have attempted to address secondary mechanisms that amplify tissue injury,11 
with particular focus on host-microbe interactions, given their ability to modulate various aspects 
of mucositis pathobiology.8 Whilst highly modifiable, this approach is again undermined by the 
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risk of impairing chemotherapy efficacy, with translocation of luminal microbes known to activate 
inflammatory pathways responsible for tumour cell death.12 Thus, more viable and promising 
molecular therapeutic targets must be identified.  
Gut-derived serotonin (5-hydroxytryptamine or 5-HT) is of particular interest in the context of 
gastrointestinal disease. Of total bodily 5-HT, 90% is synthesised, stored and released from 
enterochromaffin (EC) cells, an enteroendocrine cell that is ubiquitously expressed in the 
gastrointestinal tract mucosal lining.13 The rate-limiting enzyme in EC cell 5-HT production is 
tryptophan hydroxylase 1 (Tph1; Figure 1).14 Following basolateral excretion, seven groups of 
serotonergic receptors, some with additional subtypes, facilitate an array of physiological 
functions of mucosal 5-HT (5-HT released from EC cells).14 This includes local modulation of gut 
motility, secretion and fat absorption, as well as distal effects in organs such as the pancreas and 
liver.15 In a GIM context, the 5-HT2 receptor family is of particular interest, due to the expression 
of subtypes, 5-HT2A and 5-HT2B, throughout the gastrointestinal tract, on circular and longitudinal 
smooth muscle cells, immune cells, enterocytes and neurons.16, 17 Furthermore, these receptors 
have a determined role in stimulating gastrointestinal smooth muscle contraction and epithelial 
cell secretion,16 two regulatory mechanisms behind diarrhoea, which can be induced by 
chemotherapy via disruption of the intestinal mucosa.3  
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Whilst motility and secretion are certainly well described mediators of diarrhoea, their 
involvement in chemotherapy-induced diarrhoea (due to GIM) is less understood. Perhaps of 
greater relevance to GIM is the interaction between 5-HT and inflammation; the hallmark feature 
of GIM.7 5-HT is becoming increasingly documented to regulate acute intestinal inflammation 
through the recruitment and activation of immune cells, including eosinophils and immature 
dendritic cells.18 This is supported by investigations in various experimental models of intestinal 
inflammation, that have identified 5-HT as a key pro-inflammatory mediator.19-21 Deletion of 
serotonin reuptake transporter (SERT), an approach used to increase 5-HT availability, intensified 
inflammation in a model of TNBS-induced colitis, in mice both with and lacking IL-10.19, 20 
Alternatively, reduced 5-HT availability by both Tph1 inhibition and genetic knockout, attenuated 
the extent of intestinal inflammation in DSS- and DNBS-induced colitis mouse models.21 
Additionally, the administration of a 5-HT precursor in Tph1-deficient mice, bypassing the need 
for Tph1, was shown to increase the severity of colitis, further endorsing the pro-inflammatory 
Figure 1. Mechanism of serotonin biosynthesis in enterochromaffin cells. Enterochromaffin 
cells use rate-limiting enzyme, tryptophan hydroxylase 1 (Tph1) to convert dietary obtained 
amino acid, tryptophan, to the 5-HT precursor, 5-hydroxytryptophan (5-HTP). This product is 
then decarboxylased by amino acid decarboxylase (AADC) to finally form 5-HT. Image author 
owned and created using BioRender.com.  
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nature of 5-HT in intestinal inflammation.21 Observational preclinical studies are consistent with 
these findings, as 5-HT and EC cell levels were increased in TNBS-colitis in guinea pigs,22 and in 
infection-induced enteritis in mice.23 
5-HT has also been implicated clinically, in benign, inflammatory diseases of the gut; albeit the 
data are heterogeneous in their conclusions. In Crohn’s disease and ulcerative colitis, both 
increases and decreases in mucosal 5-HT and EC cells have been observed.24-26 Lymphocytic 
colitis patients have also displayed higher densities of 5-HT-immunoreactive cells.27 While 
directional contradictions exist, these studies irrefutably imply that 5-HT production is altered in 
states of intestinal inflammation, suggesting a possible role in GIM pathobiology. Despite this 
accumulating body of evidence implicating 5-HT in GIM, 5-HT has so far been overlooked and 
underexplored as a potential, critical candidate in GIM pathobiology. 
Study hypotheses 
Given the body of evidence implicating 5-HT in the regulation of gut motility and secretion, and 
most importantly, inflammation, this study hypothesised that: 
1. Mucosal 5-HT production increases during GIM due to up-regulation of Tph1.  
2. The expression of 5-HT gut receptors, 5-HT2A and 5-HT2B, are up-regulated during GIM. 
3. 5-HT production and receptor expression are positively correlated to GIM severity, as 
defined by weight loss, diarrhoea and small intestinal wet weight.  
Research aims 
Using archival tissue samples from a previously conducted study that used a preclinical rat model 
of GIM induced by the chemotherapeutic agent, methotrexate (MTX), this study aimed to: 
1. Determine if mucosal 5-HT and its production enzyme, Tph1, are altered by MTX. 
2. Determine if gut receptors, 5-HT2A and 5-HT2B, are altered by MTX. 
3. Determine the correlation between the changes in mucosal 5-HT and key outcome 
measures of mucositis caused by MTX.  
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Material and Methods 
Ethics 
The tissue used in this project was obtained from a 2016 study by the University of Adelaide’s 
Cancer Treatment Toxicities Group. Titled DAMX, the study was approved by the Animals Ethics 
Committee of the University of Adelaide (M-2014-144) and complied with the National Health 
and Research Council (Australia) Code of Practice for Animal Care in Research and Training 
(2014). 
DAMX Model Description  
The DAMX study used the Dark Agouti rat mammary adenocarcinoma (DAMA) model of MTX-
induced mucositis, a preclinical model of GIM validated to mirror clinically defined mechanisms 
and symptomology.28 Unlike other models of GIM, DAMA is tumour-bearing, ensuring the 
immunomodulatory properties of a tumour are reflected in the disease mechanisms of GIM. 
Furthermore, mammary adenocarcinoma cells used to inoculate the rats were isolated from a 
spontaneously arising tumour, and propagated since their initial collection. This supports their use 
in an isogenic tumour model, thus avoiding the need to immunosuppress the recipient rat.  
Induction of GIM 
Twelve female Dark Agouti rats weighing between 130-160 g were injected subcutaneously with 
mammary adenocarcinoma cells at a concentration of 2x107 cells/mL, on the right flank. 
Approximately 10 days later, upon tumours reaching 1% of total body weight (where tumour 
volume = 
(tumour width
2 x tumour length)
2 
 and tumour burden = 
tumour volume
body weight
 x 100), rats (n=6) were treated 
with the mucotoxic chemotherapeutic agent, MTX, which was administered as two intramuscular 
doses (2 mg/kg, 6.25 mg/mL). Control rats (n=6) received a volume equivalent dose of saline. All 
rats were killed by exsanguination and cervical dislocation 72 hours post initial treatment, to 




GIM Outcome Measures (DAMX) 
Body weight and diarrhoea were assessed daily, with diarrhoea defined according to a well-
established grading system, where Grade 0 = diarrhoea not present; Grade 1 = mild perianal 
staining; Grade 2 = staining on top of the legs and lower abdomen; Grade 3 = staining over the 
legs, higher abdomen and continual anal leakage.29 These criteria were used to assess GIM 
severity, as they are confirmed and reliable predictors of GIM (Table S1, supplementary material). 
Small intestinal wet weight was also defined as a primary outcome measure for the DAMX study, 
based on historical (unpublished) data from our laboratory that indicate its accuracy in objectively 
detecting GIM. As such, in addition to body weight and diarrhoea, 5-HT-related read outs were 
also correlated with small intestinal wet weight in this study. 
Tissue preparation 
Gastrointestinal tract tissue, from pyloric sphincter to rectum, was flushed with cold, isotonic 
saline following dissection. For project-relevant tissue, jejunum and proximal colon, 1 cm long 
samples were collected, snap frozen in liquid nitrogen, and stored in RNAlater (Ambion) at -80ºC 
until time of molecular analysis. In preparation for histological analysis, 1 cm segments were also 
fixed in 10% neutral buffered formalin and 70% ethanol the next day, processed and embedded in 
paraffin wax blocks, and stored at room temperature until time of analysis. 
Immunofluorescence 
5m sections of archived jejunum and proximal colon samples were cut on a rotary microtome 
(Leica RM2235), and mounted onto FLEX IHC microscope slides (Flex Plus Detection System, 
Dako; #K8020). Immunofluorescent analysis was performed for mucosal 5-HT on an automated 
immunostainer (AutostainerPlus Dako; #AS480), using and following standard Dako reagents and 
protocols. First, slides were deparaffinised by manual heating (60ºC, 15 mins) and immersion in 
histolene (3 x 5 mins), before rehydration through graded ethanols (100%, 90%, 70%) and MilliQ 
water. Next, heat-mediated antigen retrieval was carried out using a buffer (pH 9.0), comprising 
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of 0.555 g of ethylenediaminetetraacetic acid (Sigma-Aldrich), 1.815 g of Trizma® base (Sigma-
Aldrich) and 0.5mL of tween, in 1.5 L of MilliQ water. Using Dako’s PT LINK (pretreatment 
module; Dako; #PT101), the buffer was preheated to 65ºC, at which point the slides were 
immersed and the temperature raised to 97ºC for 20 minutes, before removal of the slides upon 
cooling to 65ºC. Next, non-specific staining was blocked using 10% normal horse serum (NHS) 
in 1x phosphate-buffered saline (PBS). The slides were then incubated in a primary 5-HT goat 
antibody (kindly provided by Damien Keating, Flinders University) which was diluted in 5% NHS 
(v/v with PBS) at a concentration of 1:1000 (1 g/ml). Next, a fluorescently labelled secondary 
antibody (donkey anti-goat, AlexaFluro488), diluted in 1x PBS, 1% bovine serum albumin and 
2% foetal bovine serum to a concentration of 1:250 (0.8 g/ml), was applied for a further hour. 
Slides were washed with 1x PBS and counterstained with 1 g/mL 4’,6-diamidino-2-phenylidole 
(DAPI; Life Sciences; #D1306), before treatment with an aqueous mounting medium 
(Fluoroshield™, Sigma-Aldrich, #F6182) and coverslipping. 5-HT immunofluorescence was 
quantified by blinded, manual counts of 5-HT+ cells, which were normalised to tissue area 
(determined using ImageJ).  
Real-Time Polymerase Chain Reaction (qPCR) 
RNA Extraction and Assessment of Quantity and Quality 
Ribonucleic acid (RNA) was extracted from archived tissue samples being stored in RNAlater at 
-80ºC, using the Macherey-Nagel NucleoSpin® RNA kit, following manufacturer’s guidelines. 
Upon completion of all appropriate steps, resulting RNA was eluted in 60 L of RNase-free water, 
and stored at -20ºC. Total RNA yield (ng/L) and purity was quantified and determined using a 
spectrophotometer (ThermoFisher Scientific NanoDrop 1000). Absorbance at 260 nm and 280 nm 
was measured to determine an A260:A280 ratio, which, when 2.1, indicates the absence of organic 
contaminants and proteins.30 RNA integrity was assessed by Adelaide Microarray Facility 
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(SAHMRI), with RNA integrity scores of <6.5, 6.5-8.3 and >8.3, demonstrating poor, moderate 
and good integrity, respectively. 
cDNA Conversion 
Following assessment, RNA was converted by reverse transcription into 15L of complementary 
deoxyribonucleic acid (cDNA) using a cDNA Synthesis Kit (BioRad iScriptTM), following 
manufacturer’s instructions. Each reaction consisted of 4 L of 5x iScript Reaction Mix, 1 L of 
iScript Reverse Transcriptase, and 1 g of RNA template (made up in nuclease-free water to a 
volume of 15 L). Subsequent, thermal cycling involved priming (25ºC, 5 mins), reverse 
transcription (46ºC, 20 mins) and reverse transcription inactivation (95ºC, 1 min). Sample yields 
and purities were again assessed using the spectrophotometer, with an A260:A280 ratio of 1.8 
indicating a pure sample of cDNA.30 
qPCR 
To determine the mRNA expression of the genes encoding for Tph1, 5-HT2A and 5-HT2B, qPCR 
was performed on a Rotor-Gene 3000 (Corbett Research, Sydney, Australia). Amplification 
mixtures contained 1 L of cDNA (100 ng/L), 5 L of fluorescent SYBR green dye, 3 L of 
nuclease-free water and 0.5 L of both forward and reverse primers (50 pmol/L, Table 1). All 
samples were run in triplicates. Thermal cycling conditions were dependent on primer sets (Table 
2). Suitable primers were mostly identified from the literature, including the housekeeping gene 
ubiquitin C (UBC), which has been validated for stability in GIM models.31 The 5-HT2B primers 
were designed using Primer3 (v4.0) and were based on the mRNA sequence for the Rattus 







Table 1. Primer sequences and information 







Tph132 F: CAAGGAGAACAAAGACCATTC 60.2 185 NM_001
136084.2 
R: CGCAGTCCACAAAAATCTCA 63.8 
5-HT2A 
receptor33 
F: AACGGTCCATCCACAGAG 61.2 220 NM_017
254.1 
 R: AACAGGAAGAACACGATGC 60.3 
5-HT2B 
receptor* 
F: GGAGAAAAGGCTGCAGTACG 63.8 234 NM_017
250.1 
 R: ATAACCAGGCAGGACACAGG 63.9 
UBC31 F: TCGTACCTTTCTCACCACAGTATCTAG  58.0 82 NM_017
314.1 
R: AAAACTAAGACACCTCCCCATCA 56.0  
* Designed using Primer 3. All primers synthesised by Sigma-Aldrich. 
 
Table 2. qPCR cycling conditions 
Primer set Tph1 5-HT2A 5-HT2B 
Hold 1 95ºC, 15 mins 95ºC, 10 mins 95ºC, 10 mins 
Extension 94ºC, 15 secs 95ºC, 10 secs 95ºC, 10 secs 
Denaturation 55ºC, 20 secs 60ºC, 30 secs 61ºC, 20 secs 
Annealing 72ºC, 25 secs 72ºC, 45 secs 72ºC, 30 secs 
Repeat 45 cycles 40 cycles 40 cycles 
Hold 2 72ºC, 4 mins N/A N/A 
Hold 3 60ºC, 15 secs N/A N/A 
Melt 60-99°C, hold 90 secs 
on step 1, hold 5 secs 
on next steps 
72-95°C, hold 90 secs 
on step 1, hold 5 secs 
on next steps 
72-95°C, hold 90 secs 
on step 1, hold 5 secs 
on next steps 
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Primer Efficiencies and Quantification of mRNA Expression  
Primer efficiencies were assessed using a 3-point standard curve of cDNA template (1, 10, 100 
ng/L). Despite significant optimisation, equal primer efficiencies could not be achieved, meaning 
the Ct method of quantification could not be used. Instead, mRNA expression was presented 
as 2-Ct, where Ct=Ct (UBC) - Ct (target gene). 
Statistical Analysis 
GraphPad Prism (v8.0) was used for all statistical analyses. All data were first assessed for 
normality using the Kolmogorov-Smirnov test. If normally distributed, an unpaired t-test or one-
way analysis of variance (ANOVA) was used to determine statistical significance. In cases of non-
parametric distribution, a Mann-Whitney or Kruskal Wallis test was used with appropriate post-
hoc testing. Diarrhoea scores were assessed between groups using a Chi-squared test. For 
correlative analyses, a simple XY (Pearson’s) correlation was performed, with R squared (r2)- and 
P-values generated through linear regression models. In all cases, P<0.05 was considered 




Methotrexate causes weight loss, diarrhoea and damage to the small intestine of rats 
MTX caused significant weight loss which was most severe at 72 hours (control: +5.5±0.75%, 
MTX: -9.7±0.63%, P<0.0001, Figure 2A) which coincided with peak diarrhoea severity 
(P<0.0001, Figure 2B). MTX induced significant atrophy in the small intestine, indicated by a 
decrease in wet weight (control: 4.9±0.15 mg, MTX: 3.6±0.12 mg, P<0.0001, Figure 2C). In 
contrast, a significant increase in colonic wet weight was observed at 72 hours in MTX-treated 
rats (control: 1.0±0.045 mg, MTX: 1.3±0.11 mg, P=0.045, Figure 2D). 
 
Figure 2. Model validation and clinical phenotype. MTX induces significant (A) weight 
loss (ΔBW%, mean ± SEM); (B) diarrhoea (grade scores); (C) decrease in small intestinal wet 
weight (mean ± SEM) and (D) increase in large intestinal wet weight (mean ± SEM). Data 
courtesy of Jenne Tran. 0.01 < P* < 0.05; 0.001 < P** <0.01; 0.0001 < P*** < 0.001; P**** 
< 0.0001. 
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Methotrexate impairs the production of mucosal serotonin in the jejunum of rats 
MTX decreased the number of 5-HT+ cells/m2 in the jejunum of rats (control: 0.0051±0.0010, 
MTX: 0.00045±0.00020, **P=0.0013, Figure 3A). Similarly, jejunal Tph1 mRNA expression was 
also significantly impaired by MTX (control: 470±270, MTX: 41±16, **P=0.0087, Figure 3B). 
This was in contrast to the colon where no significant changes were observed for both 5-HT+ cells 
(Figure 3C) and Tph1 expression (Figure 3D). Representative images for immunofluorescence are 
shown in Figure 4.  
Figure 3. MTX impairs enzymatic production of mucosal 5-HT in the jejunum of rats. 
Jejunal (A) number of 5-HT+ cells/m2 and (B) relative Tph1 mRNA expression of control 
(n=6) and MTX (n=5-6) animals. Proximal colonic (C) number of 5-HT+ cells/m2 and (D) 
relative Tph1 mRNA expression of control (n=6) and MTX (n=4-6) animals. Absolute cell 
counts were adjusted with respect to tissue area (m2). Data presented as mean ± SEM. 0.001 





Figure 4. Representative images of 5-HT immunofluorescence in the jejunum and 
proximal colon of control and MTX-treated rats. Samples were stained with a primary 
antibody for 5-HT, visualised using an AlexaFluor anti-goat (488 nm, green). Blue 
counterstaining (DAPI, 405 nm) shows cell nuclei. 5-HT+ cells were considered positively 
stained cells in the luminal, mucosal lining (examples indicated by arrowheads in (B), (F), (H)). 
Scale bars represent m. Original magnification, 40x. 
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Methotrexate down-regulates 5-HT2B receptor expression in the jejunum of rats 
There were no statistically significant differences in the mRNA expression of the 5HT2A receptor 
in the jejunum (Figure 5A) and colon (Figure 5B). In contrast, a significant decrease in the jejunal 
mRNA expression of the 5HT2B receptor was seen following MTX administration (control: 
9500±3300, MTX: 730±390, **P=0.0079, Figure 5C). No significant change in 5-HT2B 
















Figure 5. MTX has no effect on the expression of the 5-HT2A receptor in rats, but reduces 
5-HT2B receptor expression in the jejunum. Relative mRNA expression of 5-HT2A in the 
(A) jejunum and (B) proximal colon of control (n=5-6) and MTX (n=5) rats. Relative mRNA 
expression of 5-HT2B in the (C) jejunum and (D) proximal colon of control (n=5-6) and MTX 
(n=3-5) rats. Data presented as mean ± SEM. 
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Serotonin expression correlates with methotrexate-induced mucositis 
To understand the relationship between 5-HT synthesis and GIM severity, Pearson’s correlations 
were performed between significant 5-HT readouts in the jejunum of rats (5-HT+ cells/m2, and 
Tph1 and 5-HT2B mRNA expression) and key assessment criteria confirmed to accurately reflect 
GIM (supplementary material). Weight change relative to baseline (BW%) was significantly 
correlated with 5-HT+ cells (r2=0.72, P=0.00050) and Tph1 mRNA expression (r2=0.41, P=0.025, 
Figure 6A). Diarrhoea correlated significantly with Tph1 (r2=0.43, P=0.028) and 5-HT2B (r
2=0.58, 
P=0.010, Figure 6B) mRNA expression. Small intestinal weight was significantly correlated with 
all three markers (Figure 6C), with the strongest association to 5-HT+ cells (r2=0.71, P=0.00060), 
followed by 5-HT2B (r
2=0.65, P=0.0048) and Tph1 (r2=0.47, P=0.019) mRNA expression. 
 
Figure 6. Validated markers of GIM correlate with 5-HT production in the jejunum of 
rats. Correlations between (A) weight change; (B) diarrhoea; and (C) small intestinal wet 
weight, and adjusted 5-HT+ cell counts, relative Tph1 mRNA expression and relative 5-HT2B 
mRNA expression in the jejunum of rats.  
 
  





















































Despite significant advances in the understanding of gastrointestinal mucositis (GIM) and 
supportive care approaches, GIM remains a major dose-limiting toxicity of most anti-cancer 
therapies, and without effective intervention.1, 9 A growing body of knowledge implicates 
serotonin (5-HT) in GIM, and although a lot is known about its multiplicity of physiological roles 
in the gut, how 5-HT is altered during GIM remains poorly understood. Here, both 5-HT 
production and 5-HT2B expression were reported to be down-regulated in the jejunum of rats 
treated with methotrexate (MTX), suggesting a possible anti-inflammatory role of 5-HT in GIM 
pathobiology, which may be mediated through the 5-HT2B receptor (Figure 7). 
 
Figure 7. Proposed role of 5-HT in GIM pathobiology, explaining the observed results of 
this study. 
 19 
Multiple reports from experimentally-induced colitis implicate 5-HT in inflammatory bowel 
diseases (IBD), with most supporting a pro-inflammatory role. It is important to note, that while 
comparable, IBD and GIM have distinct pathobiologies (chronic, colon-specific versus acute, pan-
intestinal), so common mechanisms should be considered and interpreted carefully. Nonetheless, 
increasing 5-HT availability during colitis via SERT knockout, heightened intestinal inflammation 
intensity,19, 20 while decreasing 5-HT availability with either Tph1 inhibition or knockout, reduced 
the severity of colitis inflammation.21 Conversely, and refuting the hypotheses of this study, my 
results clearly indicate deficient 5-HT production during gut inflammation, with both 5-HT+ 
cells/m2 and the Tph1 enzyme down-regulated in the jejunum of MTX-treated rats. If considered 
independently, this observed reduction in 5-HT+ cells might be explainable by considering 
possible timelines of 5-HT release from enterochromaffin (EC) cells with respect to the analysed 
time-point (72-hours post MTX treatment). That is, perhaps EC cells responded to MTX by rapid, 
hypersecretion of 5-HT within 72 hours after treatment. Alternatively, it is possible that MTX 
causes such severe mucosal damage and significant tissue atrophy, directly decreasing the number 
of 5-HT+ cells. However, given that cell counts were adjusted to tissue area, and Tph1 expression 
itself was also reduced, it is more likely that the fundamental, enzymatic production of 5-HT is 
altered by MTX-induced GIM.  
The concept that 5-HT is pro-inflammatory has largely been based on its positive correlation with 
IBD. However, an increasing body of research is beginning to challenge this exclusivity, with 
emerging data suggesting possible anti-inflammatory roles for 5-HT. For example, decreased 5-
HT levels in the inflamed mucosa of IBD patients are proposed to be driven by damage to the 
cellular constituents responsible for 5-HT production.26 Similarly, in addition to the loss of 5-HT 
producing EC cells, ulcerative colitis patients also exhibited depleted mucosal 5-HT and Tph1 
mRNA expression, suggesting an inverse relationship with inflammation and supporting the 
results of this study.25  
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Although informative, these studies are limited, only detailing associations between 5-HT and 
diseases characterised by mucosal inflammation. More recently, a true anti-inflammatory 
mechanism was identified for 5-HT. Systemic and selective 5-HT2A receptor activation with 
agonist (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, or (R)-DOI, proved to induce a 
systemic blockade of TNF effects,34 a pro-inflammatory cytokine that is elevated in GIM7. This 
resulted in particularly profound anti-inflammatory effects in the small intestine, as well as 
prevention of a TNF-induced increase in circulating IL-6,34 another cytokine implicated in GIM-
inflammation.7 These findings are particularly relevant to my study, as these anti-inflammatory 
effects of 5-HT were reported to be dependent on 5-HT2A activation, highlighting the potential for 
agonism of this receptor to alleviate inflammatory gut disorders.34 While I identified a change in 
5-HT2B expression, together these results indicate that the anti-inflammatory actions of 5-HT may 
be mediated by the 5HT2 receptor, suggesting 5-HT supplementation and/or 5-HT2 agonism are 
potential approaches to alleviate GIM-inflammation. 
Excitingly, 5-HT2B agonism to alleviate inflammation has recently shown promise in experiments 
on a subset of human monocyte-derived dendritic cells (moDCs), CD1a+, which are crucial to both 
innate and adaptive inflammatory responses.35 CD1a+ moDCs were treated with a synthetic toll-
like receptor 3 ligand, polyinosinic:polycytidylic acid, or polyI:C, to elicit a strong inflammatory 
response. Following this, receptor activation with a highly selective 5-HT2B agonist proved to 
decrease both mRNA expression and secreted levels of pro-inflammatory cytokines, TNF and 
IL-6, as well as IL-8 and IL-10.35 In addition, ligation of 5-HT2B blocked the adaptive 
inflammatory response of T helper (Th) cells, Th1 and Th17. Furthermore, 5-HT2B blocking 
experiments with an anti-5-HT2B polyclonal antibody, confirmed the proposed, 
immunomodulatory effects of 5-HT2B. Altogether, these findings, along with the results of my 
study, promote the candidacy of 5-HT2B as a pharmacological target for both acute and chronic 
inflammatory disorders.35 
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Before overstating the potential of 5-HT supplementation (through 5-HT2B agonism) as an 
approach to attenuate GIM-inflammation, it is important to decipher what my results mean in 
terms of how 5-HT is implicated in GIM pathobiology. That is, is it simply an innocent bystander 
that is affected by mucosal injury but has no direct part in exacerbating the disease, or, is it an 
active culprit that contributes to tissue injury and symptomology? To elucidate this, correlative 
strength between 5-HT readouts and key outcome measures of GIM was evaluated (Figure 6). 
While this approach cannot dissect its causative contribution, it is evident that 5-HT is intimately 
involved with mucosal injury and symptomology. This warrants further investigation into its 
active contribution, despite the inherit challenge in deducing cause and consequence in GIM. One 
potential approach would be utilising a 5-HT knockout organism in a validated model of GIM. 
Various methods of manipulating 5-HT availability, such as SERT19, 20 and Tph121 knockouts, 
have already been validated in IBD studies as reliable approaches to dissect causative mechanisms 
in a complex disease process, where significant collateral damage is evident.  
It is also important to acknowledge the existing understanding of 5-HT in cancer therapy, in 
particular, its well-established role in chemotherapy-induced nausea and vomiting (CINV). 
Chemotherapy, including MTX, is well-documented to disrupt EC cells, causing a massive, local 
release of 5-HT, which eventuates in acute- and delayed-onset nausea through the activation of 5-
HT3 and NK1 receptors in the chemoreceptor trigger zone.
36, 37 Thus, 5-HT’s established role in 
CINV could undermine the viability of therapeutic 5-HT supplementation for the mediation of 
GIM. Therefore, robust investigation should be done to determine if 5-HT supplementation is able 
to mitigate GIM-inflammation, and whether such supplementation can be achieved in a gut-
localised manner, to avoid CINV side effects. One possible intervention that could facilitate this, 
is nanotechnology, in which drugs are directed to the site of action. This approach has already 
shown promise in minimising gut-inflammation in an IBD setting, with a glucagon-like peptide 1 
nanomedicine demonstrating preclinical efficacy in a mouse model of colitis.38 
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Whilst there is the potential to exacerbate CINV, it is also important to highlight that 5-HT 
supplementation may have wider reaching benefits for people with cancer, owing to its pro-
neuropsychological mechanisms that affect mood, cognition and sleep.35, 39 This is particularly 
important in a supportive oncology setting where mood and sleep disturbances are commonly 
reported in cancer patients, yet remain without effective intervention.39 This presents a novel 
opportunity to simultaneously address multiple side effects of cancer treatment, while also 





The complexity of the pathobiology behind chemotherapy-induced GIM is reflected by the current 
absence of an effective therapeutic intervention. This study demonstrated, for the first time, that 
MTX-induced GIM impairs 5-HT production and 5-HT2B receptor expression in the small 
intestine of rats. In light of a strong relationship with key outcome criteria of GIM, this loss in 5-
HT is proposed as a probable contributor to mucosal injury and symptomology, via anti-
inflammatory pathways (Figure 7). These data support follow up studies that challenge the existing 
idea of the pro-inflammatory nature of 5-HT, and aim to i) confirm the true contribution of 5-HT 
to GIM through genetic modification and ii) elucidate whether 5-HT supplementation is a viable 
therapeutic approach for GIM. Finally, while this approach has the multi-dimensional potential to 
simultaneously minimise gut injury and enhance cancer-induced impairments in mood and 
sleeping patterns, it must be approached with particular caution, due to the possibility of 
exacerbating 5-HT dependent nausea and vomiting.
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Although histopathological analysis is currently deemed the “gold-standard” in characterising 
mucositis severity, it is not without limitations, which include the subjective grading of various 
criteria and the necessity of necroscopy. While non-lethal clinical outcome measures, such as 
diarrhoea severity and weight loss, accurately represent the clinical phenotype of GIM, they are 
only assumed to be indicative of fundamental histological damage, as currently, no evidence in 
the literature has confirmed this. Therefore, to determine which non-lethal, clinical outcome 
measures most accurately predict the histopathological damage of mucositis, correlative, followed 
by multivariate statistical analysis, was performed on an abundance of archival rodent (mouse and 
rat) data. Results revealed diarrhoea severity and weight loss to be the most suitable non-lethal 
predictors of histological damage, and therefore GIM severity, as indicated by a statistically 
significant (P<0.05) correlation of these factors with markers of histopathological damage (Table 
S1). These determined, non-lethal predictors, were then used to correlate changes in 5-HT 
production and receptor expression with mucositis. 
Table S1. Multivariable binary logistic regressions of GIM outcome measures relative to 
histologically confirmed GIM. 






(jejunum and colon) 
Weight (per 1% increase 
from baseline) 
0.81 (0.69, 0.96) 0.0129 
Colon mucositis Diarrhoea grade: per 1 
unit increase 
3.82 (1.07, 13.64) 0.0393 
 
 
